PE20090945A1 - Composiciones farmaceuticas que comprenden un precursor de esteroides sexuales - Google Patents

Composiciones farmaceuticas que comprenden un precursor de esteroides sexuales

Info

Publication number
PE20090945A1
PE20090945A1 PE2008001360A PE2008001360A PE20090945A1 PE 20090945 A1 PE20090945 A1 PE 20090945A1 PE 2008001360 A PE2008001360 A PE 2008001360A PE 2008001360 A PE2008001360 A PE 2008001360A PE 20090945 A1 PE20090945 A1 PE 20090945A1
Authority
PE
Peru
Prior art keywords
steroid precursor
pharmaceutical compositions
compositions including
sexual steroid
sexual
Prior art date
Application number
PE2008001360A
Other languages
English (en)
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of PE20090945A1 publication Critical patent/PE20090945A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN PRECURSOR DE ESTEROIDES SEXUALES SELECCIONADO DE DEHIDROEPIANDROSTERONA, ANDROST-5-EN-3BETA,17BETA-DIOL Y 4-ANDROSTEN-3,17-DIONA Y UN EXCIPIENTE TAL COMO MANTECA, ACEITE DE PALMA, ACEITE DE GRANOS DE PALMERA, ACEITE DE ALGODON, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE TRANSTORNOS DEBIDOS A LA MENOPAUSIA TALES COMO OSTEOPOROSIS, ATROFIA DE LA PIEL, PERDIDA DE MASA MUSCULAR, LIBIDO DISMINUIDA, ENTRE OTROS
PE2008001360A 2007-08-10 2008-08-11 Composiciones farmaceuticas que comprenden un precursor de esteroides sexuales PE20090945A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96427007P 2007-08-10 2007-08-10
US96467307P 2007-08-13 2007-08-13
US12/221,847 US8268806B2 (en) 2007-08-10 2008-08-07 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PE20090945A1 true PE20090945A1 (es) 2009-07-08

Family

ID=40350317

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001360A PE20090945A1 (es) 2007-08-10 2008-08-11 Composiciones farmaceuticas que comprenden un precursor de esteroides sexuales
PE2013001547A PE20140925A1 (es) 2007-08-10 2008-08-11 Composicion farmaceutica que comprende un precursor de esteroides sexuales

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2013001547A PE20140925A1 (es) 2007-08-10 2008-08-11 Composicion farmaceutica que comprende un precursor de esteroides sexuales

Country Status (28)

Country Link
US (5) US8268806B2 (es)
EP (2) EP2185157B1 (es)
JP (2) JP5725283B2 (es)
KR (3) KR101850125B1 (es)
CN (4) CN105412121A (es)
AR (2) AR068702A1 (es)
AU (1) AU2008286651B2 (es)
BR (1) BRPI0815353A2 (es)
CA (2) CA2696127C (es)
CO (1) CO6260084A2 (es)
DK (1) DK2185157T3 (es)
EA (2) EA020683B1 (es)
EC (1) ECSP10010016A (es)
ES (1) ES2888104T3 (es)
HK (1) HK1217639A1 (es)
IL (1) IL203747A (es)
MA (1) MA31694B1 (es)
MX (1) MX2010001627A (es)
NO (1) NO20100300L (es)
NZ (2) NZ583147A (es)
PE (2) PE20090945A1 (es)
PH (1) PH12013502291A1 (es)
PT (1) PT2185157T (es)
SA (2) SA08290494B1 (es)
SG (3) SG10201601242TA (es)
TN (1) TN2010000065A1 (es)
TW (3) TWI388328B (es)
WO (1) WO2009021323A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7258996A (en) * 1995-10-06 1997-04-28 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
WO2006042409A1 (en) 2004-10-20 2006-04-27 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
EP2034984A4 (en) 2006-06-02 2013-03-06 Pear Tree Women S Health Care PROCESS FOR TREATING ATROPHIC VAGINITIS
US9284345B2 (en) * 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
JP2012523434A (ja) * 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9066956B2 (en) * 2011-12-29 2015-06-30 Universidad De Chile Vaginal ring comprising DHEA or DHEA sulfate and optionally a release-modulating agent of the active principle, useful to increase the ovarian reserve in women and to relieve symptoms associated with menopause
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20140045806A1 (en) * 2012-07-25 2014-02-13 Fernand Labrie Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
JP2017523138A (ja) 2014-07-29 2017-08-17 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 経皮クリーム
RU2691652C2 (ru) * 2014-10-16 2019-06-17 ДжиТиИкс, ИНК. Способы лечения урологических нарушений с применением селективных модуляторов андрогеновых рецепторов
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9862101B2 (en) 2015-12-22 2018-01-09 Varian Semiconductor Equipment Associats, Inc. Self-damping end effector
RU2618428C1 (ru) * 2016-03-24 2017-05-03 Общество с ограниченной ответственностью "Научно-производственное предприятие Лаборатория Матрикс" Комплексное косметическое средство
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN109350624A (zh) * 2018-05-25 2019-02-19 泓博元生命科技（深圳）有限公司 含有nmn和dhea的女性保健组合物、制剂及其制备方法与应用
CN109364171A (zh) * 2018-05-25 2019-02-22 泓博元生命科技（深圳）有限公司 含有nadh和dhea的卵巢保养组合物、制剂及其制备方法
BR112021019560A2 (pt) * 2019-03-29 2021-12-21 Bridget Martell Anéis intravaginais de eva segmentados contendo progesterona
JP6945874B2 (ja) * 2019-12-24 2021-10-06 一般財団法人バイオダイナミックス研究所 経口投与用医薬組成物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2024068968A1 (en) * 2022-09-29 2024-04-04 Rigshospitalet Inhibition of luteinizing hormone (lh) action as treatment of perimenopausal and postmenopausal symptoms and complications

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63104924A (ja) * 1986-10-20 1988-05-10 Kanebo Ltd 膣坐剤
US4835147A (en) 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5407684A (en) * 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5246704A (en) * 1989-01-23 1993-09-21 Kanebo, Ltd. Vaginal suppository
HU221589B (hu) 1989-03-10 2002-11-28 Endorecherche Inc. Emlő- és méhrák kezelésére alkalmas kombinációs gyógyszerkészítmény és eljárás előállítására
WO1991000731A1 (en) 1989-07-07 1991-01-24 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
CA2062792C (en) 1989-07-07 2006-03-21 Fernard Labrie Treatment of androgen-related diseases
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
NZ512334A (en) * 1993-01-19 2005-05-27 Endorech Inc Therapeutic methods and delivery systems utilizing sex steroid precursors
JP2698865B2 (ja) * 1994-08-08 1998-01-19 仲昭 大澤 筋緊張性ジストロフィー症治療剤
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
CA2241623A1 (en) 1996-01-11 1997-07-17 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
BR9706966A (pt) 1996-01-11 1999-05-04 Novo Nordisk As Utilização do enanciômero-l de um composto e processo para tratamento ou profilaxia de câncer da mama
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
DE69707189T2 (de) 1996-04-19 2002-06-20 American Home Prod Östrogene Verbindungen
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6013665A (en) * 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
CN1879630A (zh) 1998-06-11 2006-12-20 内部研究股份有限公司 雄－5－烯－3β,17β－二醇的药物组合物及其用途
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6007824A (en) 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
US20030181353A1 (en) * 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
PE20010404A1 (es) * 1999-06-11 2001-04-09 Watson Pharmaceuticals Inc Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres
US7452545B2 (en) * 2001-11-13 2008-11-18 Yu Ruey J Oligosaccharide aldonic acids and their topical use
US6335023B1 (en) * 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US20070042060A1 (en) * 1999-07-01 2007-02-22 Thompson Ronald J Methods to treat one or all of the defined etiologies of female sexual Dysfunction
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20020165429A1 (en) * 1999-07-01 2002-11-07 40 J's Llc Clitoral sensitizing arrangements
AU5957500A (en) 1999-07-06 2001-01-22 Endorecherche Inc. Methods of treating and/or suppressing weight gain
WO2001054699A1 (en) 2000-01-28 2001-08-02 Endorecherche, Inc. Selective estrogen receptor modulators in combination with estrogens
US20020022052A1 (en) * 2000-04-06 2002-02-21 Dransfield Charles William Transdermal delivery system
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US20040092583A1 (en) * 2001-01-02 2004-05-13 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions
AU2002303427A1 (en) * 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
AU2002256359A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
WO2002092102A2 (en) 2001-05-16 2002-11-21 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
FR2828100B1 (fr) 2001-08-02 2004-09-24 Galderma Res & Dev Composition de type emulsion inverse contenant de la dhea et/ou ses precurseurs ou derives, et ses utilisations en cosmetique et en dermatologie
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7348352B2 (en) * 2001-10-23 2008-03-25 Bioresponse L.L.C. Diindolylmethane for the treatment of HPV infection
US20040259850A1 (en) * 2001-10-31 2004-12-23 Alves Stephen E. Method for treating or preventing symptoms of hormonal variation including hot flashes
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20040033963A1 (en) * 2002-04-10 2004-02-19 Yu Ruey J. Urea composition
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
CN1930181A (zh) 2004-01-07 2007-03-14 恩多研究公司 螺旋12定向的甾族药品
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
US20080119445A1 (en) * 2004-09-08 2008-05-22 Woodward John R Methods of female sexual enhancement
US20060276442A1 (en) * 2004-09-08 2006-12-07 Woodward John R Methods of female sexual enhancement
US20060252734A1 (en) * 2004-09-08 2006-11-09 Woodward John R Methods of female sexual enhancement
WO2006042409A1 (en) 2004-10-20 2006-04-27 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
JP2008517952A (ja) 2004-11-01 2008-05-29 アンドルシェルシュ・インコーポレイテッド 皮膚老化となる可能性を低下させるための、または皮膚老化を処置するためのアンドロゲンの使用
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
EP1890704A1 (en) 2005-12-16 2008-02-27 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
US8021659B2 (en) * 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
JP4179624B2 (ja) * 2006-07-18 2008-11-12 ヒロセ電機株式会社 平型導体用電気コネクタ
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators

Also Published As

Publication number Publication date
AR068702A1 (es) 2009-12-02
TWI388328B (zh) 2013-03-11
PH12013502291B1 (en) 2015-09-07
TW200927136A (en) 2009-07-01
JP5725283B2 (ja) 2015-05-27
EA201000312A1 (ru) 2010-08-30
JP6197292B2 (ja) 2017-09-20
SG10201601242TA (en) 2016-03-30
AU2008286651B2 (en) 2012-11-22
TWI609688B (zh) 2018-01-01
CO6260084A2 (es) 2011-03-22
KR20100061671A (ko) 2010-06-08
KR101638130B1 (ko) 2016-07-08
PE20140925A1 (es) 2014-08-09
JP2013060475A (ja) 2013-04-04
EA020683B1 (ru) 2015-01-30
EP2185157A4 (en) 2010-11-03
US20130005700A1 (en) 2013-01-03
AR114051A2 (es) 2020-07-15
KR20160032257A (ko) 2016-03-23
KR20130103805A (ko) 2013-09-24
NZ583147A (en) 2012-04-27
US8268806B2 (en) 2012-09-18
SA111320726B1 (ar) 2015-08-10
CA2696127C (en) 2017-06-06
CN109893526A (zh) 2019-06-18
BRPI0815353A2 (pt) 2015-06-16
SG183702A1 (en) 2012-09-27
US8957054B2 (en) 2015-02-17
JP2010535717A (ja) 2010-11-25
PT2185157T (pt) 2021-03-15
ES2888104T3 (es) 2021-12-30
US10881650B2 (en) 2021-01-05
TWI565468B (zh) 2017-01-11
US20120283230A1 (en) 2012-11-08
MA31694B1 (fr) 2010-09-01
PH12013502291A1 (en) 2015-09-07
EP2441456A1 (en) 2012-04-18
MX2010001627A (es) 2010-09-14
CA2820566C (en) 2016-09-13
CN101861152A (zh) 2010-10-13
KR101850125B1 (ko) 2018-04-19
US20120322778A1 (en) 2012-12-20
EA201200369A1 (ru) 2012-09-28
KR101680287B1 (ko) 2016-11-28
WO2009021323A1 (en) 2009-02-19
CA2696127A1 (en) 2009-02-19
ECSP10010016A (es) 2010-07-30
SG10201902375XA (en) 2019-04-29
CN105412121A (zh) 2016-03-23
NO20100300L (no) 2010-04-29
NZ598270A (en) 2013-08-30
US20090054383A1 (en) 2009-02-26
US8629129B2 (en) 2014-01-14
EP2185157B1 (en) 2020-12-16
US20210069169A1 (en) 2021-03-11
DK2185157T3 (da) 2021-03-08
CN102861335A (zh) 2013-01-09
IL203747A (en) 2016-09-29
SA08290494B1 (ar) 2013-04-20
AU2008286651A1 (en) 2009-02-19
EP2185157A1 (en) 2010-05-19
TN2010000065A1 (en) 2011-09-26
TW201634051A (zh) 2016-10-01
TW201212922A (en) 2012-04-01
EP2441456B1 (en) 2021-10-06
HK1217639A1 (zh) 2017-01-20
CA2820566A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
PE20090945A1 (es) Composiciones farmaceuticas que comprenden un precursor de esteroides sexuales
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BR112012000204A8 (pt) Composição farmacêutica em forma de dosagem unitária que compreende apomorfina e seu uso
ECSP078066A (es) Composiciones y metodos para el tratamiento de síntomas relacionados al ciclo
PE20181523A1 (es) Tratamiento de lupus nefritis usando laquinimod
JP2012532093A5 (es)
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
CR11723A (es) Agente para tratar enfermedad
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
CO6251259A2 (es) Formulaciones farmaceuticas de estriol en baja dosis
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
JP2014001235A5 (es)
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
RU2012125827A (ru) Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
BR112012010070A2 (pt) pterostilbeno (pter) para uso na prevenção e/ou tratamento de doenças, danos ou ferimentos na pele
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
MX2009010989A (es) Composiciones farmaceuticas liofilizadas y metodos de obtener y usar las mismas.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
NZ599839A (en) Synergistic antiviral composition and use thereof
UY37577A (es) Dihidroimidazopiridindionas sustituidas
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
GT200900235A (es) Composiciones farmaceuticas

Legal Events

Date Code Title Description
FG Grant, registration